Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 23

1.

CDK11 Loss Induces Cell Cycle Dysfunction and Death of BRAF and NRAS Melanoma Cells.

Ahmed RL, Shaughnessy DP, Knutson TP, Vogel RI, Ahmed K, Kren BT, Trembley JH.

Pharmaceuticals (Basel). 2019 Apr 2;12(2). pii: E50. doi: 10.3390/ph12020050.

2.

Evaluation of protein kinase CK2 as a therapeutic target for squamous cell carcinoma of cats.

Cannon CM, Trembley JH, Kren BT, Unger GM, O'Sullivan MG, Cornax I, Modiano JF, Ahmed K.

Am J Vet Res. 2017 Aug;78(8):946-953. doi: 10.2460/ajvr.78.8.946.

PMID:
28738012
3.

Therapeutic Targeting of Protein Kinase CK2 Gene Expression in Feline Oral Squamous Cell Carcinoma: A Naturally Occurring Large-Animal Model of Head and Neck Cancer.

Cannon CM, Trembley JH, Kren BT, Unger GM, O'Sullivan MG, Cornax I, Modiano JF, Ahmed K.

Hum Gene Ther Clin Dev. 2017 Jun;28(2):80-86. doi: 10.1089/humc.2017.008. Epub 2017 Mar 23.

4.

CK2 Molecular Targeting-Tumor Cell-Specific Delivery of RNAi in Various Models of Cancer.

Trembley JH, Kren BT, Abedin MJ, Vogel RI, Cannon CM, Unger GM, Ahmed K.

Pharmaceuticals (Basel). 2017 Feb 21;10(1). pii: E25. doi: 10.3390/ph10010025. Review.

5.

CK2 targeted RNAi therapeutic delivered via malignant cell-directed tenfibgen nanocapsule: dose and molecular mechanisms of response in xenograft prostate tumors.

Ahmed K, Kren BT, Abedin MJ, Vogel RI, Shaughnessy DP, Nacusi L, Korman VL, Li Y, Dehm SM, Zimmerman CL, Niehans GA, Unger GM, Trembley JH.

Oncotarget. 2016 Sep 20;7(38):61789-61805. doi: 10.18632/oncotarget.11442.

6.

Examination of CK2α and NF-κB p65 expression in human benign prostatic hyperplasia and prostate cancer tissues.

Qaiser F, Trembley JH, Sadiq S, Muhammad I, Younis R, Hashmi SN, Murtaza B, Rector TS, Naveed AK, Ahmed K.

Mol Cell Biochem. 2016 Sep;420(1-2):43-51. doi: 10.1007/s11010-016-2765-3. Epub 2016 Jul 19.

PMID:
27435858
7.

Growth inhibition and apoptosis in cancer cells induced by polyphenolic compounds of Acacia hydaspica: Involvement of multiple signal transduction pathways.

Afsar T, Trembley JH, Salomon CE, Razak S, Khan MR, Ahmed K.

Sci Rep. 2016 Mar 15;6:23077. doi: 10.1038/srep23077.

8.

Preclinical evaluation of cyclin dependent kinase 11 and casein kinase 2 survival kinases as RNA interference targets for triple negative breast cancer therapy.

Kren BT, Unger GM, Abedin MJ, Vogel RI, Henzler CM, Ahmed K, Trembley JH.

Breast Cancer Res. 2015;17:19. doi: 10.1186/s13058-015-0524-0. Epub 2015 Feb 11.

9.

Tenfibgen ligand nanoencapsulation delivers bi-functional anti-CK2 RNAi oligomer to key sites for prostate cancer targeting using human xenograft tumors in mice.

Trembley JH, Unger GM, Korman VL, Abedin MJ, Nacusi LP, Vogel RI, Slaton JW, Kren BT, Ahmed K.

PLoS One. 2014 Oct 15;9(10):e109970. doi: 10.1371/journal.pone.0109970. eCollection 2014.

10.

Protein kinase CK2 inhibition induces cell death via early impact on mitochondrial function.

Qaiser F, Trembley JH, Kren BT, Wu JJ, Naveed AK, Ahmed K.

J Cell Biochem. 2014 Dec;115(12):2103-15. doi: 10.1002/jcb.24887.

11.

Mechanism and efficacy of sub-50-nm tenfibgen nanocapsules for cancer cell-directed delivery of anti-CK2 RNAi to primary and metastatic squamous cell carcinoma.

Unger GM, Kren BT, Korman VL, Kimbrough TG, Vogel RI, Ondrey FG, Trembley JH, Ahmed K.

Mol Cancer Ther. 2014 Aug;13(8):2018-29. doi: 10.1158/1535-7163.MCT-14-0166. Epub 2014 May 27.

12.

Tenfibgen-DMAT Nanocapsule Delivers CK2 Inhibitor DMAT to Prostate Cancer Xenograft Tumors Causing Inhibition of Cell Proliferation.

Trembley JH, Unger GM, Gomez OC, Abedin J, Korman VL, Vogel RI, Niehans G, Kren BT, Ahmed K.

Mol Cell Pharmacol. 2014;6(2):15-25.

13.

Nanoencapsulated anti-CK2 small molecule drug or siRNA specifically targets malignant cancer but not benign cells.

Trembley JH, Unger GM, Korman VL, Tobolt DK, Kazimierczuk Z, Pinna LA, Kren BT, Ahmed K.

Cancer Lett. 2012 Feb 1;315(1):48-58. doi: 10.1016/j.canlet.2011.10.007. Epub 2011 Oct 12.

14.

Systemic administration of antisense oligonucleotides simultaneously targeting CK2α and α' subunits reduces orthotopic xenograft prostate tumors in mice.

Trembley JH, Unger GM, Tobolt DK, Korman VL, Wang G, Ahmad KA, Slaton JW, Kren BT, Ahmed K.

Mol Cell Biochem. 2011 Oct;356(1-2):21-35. doi: 10.1007/s11010-011-0943-x. Epub 2011 Jul 15.

15.

The RNA binding motif protein 15B (RBM15B/OTT3) is a functional competitor of serine-arginine (SR) proteins and antagonizes the positive effect of the CDK11p110-cyclin L2α complex on splicing.

Loyer P, Busson A, Trembley JH, Hyle J, Grenet J, Zhao W, Ribault C, Montier T, Kidd VJ, Lahti JM.

J Biol Chem. 2011 Jan 7;286(1):147-59. doi: 10.1074/jbc.M110.192518. Epub 2010 Nov 2.

16.

Emergence of protein kinase CK2 as a key target in cancer therapy.

Trembley JH, Chen Z, Unger G, Slaton J, Kren BT, Van Waes C, Ahmed K.

Biofactors. 2010 May-Jun;36(3):187-95. doi: 10.1002/biof.96. Review.

17.

Characterization of cyclin L1 and L2 interactions with CDK11 and splicing factors: influence of cyclin L isoforms on splice site selection.

Loyer P, Trembley JH, Grenet JA, Busson A, Corlu A, Zhao W, Kocak M, Kidd VJ, Lahti JM.

J Biol Chem. 2008 Mar 21;283(12):7721-32. doi: 10.1074/jbc.M708188200. Epub 2008 Jan 23.

18.

Role of CDK/cyclin complexes in transcription and RNA splicing.

Loyer P, Trembley JH, Katona R, Kidd VJ, Lahti JM.

Cell Signal. 2005 Sep;17(9):1033-51. Review.

PMID:
15935619
19.

Activation of pre-mRNA splicing by human RNPS1 is regulated by CK2 phosphorylation.

Trembley JH, Tatsumi S, Sakashita E, Loyer P, Slaughter CA, Suzuki H, Endo H, Kidd VJ, Mayeda A.

Mol Cell Biol. 2005 Feb;25(4):1446-57.

20.

Cyclin dependent kinase 11 in RNA transcription and splicing.

Trembley JH, Loyer P, Hu D, Li T, Grenet J, Lahti JM, Kidd VJ.

Prog Nucleic Acid Res Mol Biol. 2004;77:263-88. Review. No abstract available.

PMID:
15196895

Supplemental Content

Loading ...
Support Center